List of Excipients in Branded Drug PRECOSE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Aphena Pharma Solutions - Tennessee LLC	PRECOSE	acarbose	43353-908	CELLULOSE, MICROCRYSTALLINE
Aphena Pharma Solutions - Tennessee LLC	PRECOSE	acarbose	43353-908	MAGNESIUM STEARATE
Aphena Pharma Solutions - Tennessee LLC	PRECOSE	acarbose	43353-908	SILICON DIOXIDE
Aphena Pharma Solutions - Tennessee LLC	PRECOSE	acarbose	43353-908	STARCH, CORN
Bayer HealthCare Pharmaceuticals Inc	PRECOSE	acarbose	50419-863	CELLULOSE, MICROCRYSTALLINE
Bayer HealthCare Pharmaceuticals Inc	PRECOSE	acarbose	50419-863	MAGNESIUM STEARATE
Bayer HealthCare Pharmaceuticals Inc	PRECOSE	acarbose	50419-863	SILICON DIOXIDE

Precose (Acarbose) Excipient Strategy and Commercial Opportunities

Last updated: September 26, 2026

Precose is the former Bayer brand for acarbose, an oral alpha-glucosidase inhibitor used with diet and exercise to improve glycemic control in adults with type 2 diabetes. The product is an immediate-release tablet available at 25 mg, 50 mg, and 100 mg strengths. Its commercial opportunity is primarily generic and formulation-driven: lower-cost tablets, improved swallowability, adherence-focused presentations, and differentiated regional products rather than new chemical-entity exclusivity.

Acarbose acts locally in the gastrointestinal tract. Its limited systemic absorption reduces the value of traditional systemic bioavailability optimization and increases the importance of rapid tablet dispersion, excipient compatibility, dose uniformity, and gastrointestinal tolerability. FDA labeling directs patients to take acarbose orally three times daily with the first bite of each main meal.[1]

What is Precose and how does acarbose work?

Precose contains acarbose, a complex oligosaccharide that delays carbohydrate digestion by inhibiting intestinal alpha-amylase and alpha-glucosidase enzymes. The resulting reduction in postprandial glucose absorption is the product’s principal pharmacologic effect.[1]

Acarbose is administered before or with meals. The labeled dosing sequence is clinically important because the product acts on carbohydrate digestion during food transit rather than through sustained systemic exposure.

Attribute	Precose / acarbose
Active ingredient	Acarbose
Drug class	Alpha-glucosidase inhibitor
Main indication	Type 2 diabetes
Dosage form	Immediate-release oral tablet
Strengths	25 mg, 50 mg, 100 mg
Administration	With the first bite of each main meal
Typical dosing frequency	Three times daily
Primary effect	Reduction of postprandial plasma glucose
Main tolerability issue	Flatulence, diarrhea, abdominal discomfort
Systemic exposure	Low; activity is primarily gastrointestinal

Acarbose is not an insulin secretagogue. It does not generally cause hypoglycemia when used alone, although hypoglycemia risk can increase when combined with insulin or insulin secretagogues.[1]

What excipients are used in Precose tablets?

The U.S. Precose labeling identifies conventional tablet excipients, including colloidal silicon dioxide, corn starch, magnesium stearate, and microcrystalline cellulose.[1] Excipients may vary among generic manufacturers, strengths, and jurisdictions.

These ingredients support a conventional immediate-release formulation:

Excipient category	Likely function in acarbose tablets	Commercial relevance
Microcrystalline cellulose	Diluent and dry binder	Supports tablet strength and manufacturability
Corn starch	Disintegrant and filler	Promotes breakup after ingestion
Colloidal silicon dioxide	Glidant and moisture-management aid	Improves powder flow and blend uniformity
Magnesium stearate	Lubricant	Reduces tooling friction and ejection force
Film-coating system, where used	Protection, appearance, swallowability	Can improve handling but may slow disintegration if over-engineered

The formulation target is not prolonged release. Acarbose should disperse in the gastrointestinal lumen in time to interact with dietary carbohydrates. Excessive compression force, high hydrophobic lubricant levels, or a dense coating can delay disintegration and weaken the product’s functional performance.

How should an acarbose excipient strategy be designed?

The strongest strategy is a robust immediate-release platform with controlled tablet size, fast disintegration, low friability, and acceptable mouthfeel.

Optimize disintegration without increasing gastrointestinal burden

Acarbose already produces gastrointestinal symptoms through its pharmacology. Excipients should not add substantial osmotic load, irritation, or poorly tolerated fermentable carbohydrate content. Formulators should evaluate:

• Crospovidone, croscarmellose sodium, or sodium starch glycolate as alternative superdisintegrants.
• Low-substitution hydroxypropyl cellulose or other dry binders where stronger tablets are required.
• Direct compression when powder flow and blend uniformity are adequate.
• Wet granulation only when needed to control segregation, density, or compression behavior.
• Reduced magnesium stearate concentration and controlled lubrication time to avoid hydrophobicity.
• Low-moisture excipients and packaging where moisture affects hardness, dissolution, or stability.

A starch-based system is commercially practical, but a modern superdisintegrant platform may permit smaller tablets and lower compression force.

Control dose uniformity across three strengths

The 25 mg strength can create the greatest content-uniformity challenge because the active represents a smaller share of total tablet mass. A robust process may use geometric dilution, ordered blending, or granulation to prevent segregation.

The 100 mg strength creates a different issue: tablet size and swallowability. A high-dose product that is physically large may reduce adherence, particularly because treatment requires administration with every main meal.

An excipient platform that uses the same manufacturing process across 25 mg, 50 mg, and 100 mg can reduce validation cost and simplify supply. The formulation should preserve common tooling, comparable dissolution behavior, and predictable scale-up.

Consider direct compression for cost reduction

Direct compression can reduce equipment requirements and solvent exposure. It is attractive for a mature generic product if acarbose has adequate flow and acceptable compactibility after blending with a suitable filler-binder system.

A dry granulation route may be preferable where the active or excipient blend has poor flow, low bulk density, or segregation risk. Wet granulation can improve content uniformity but introduces drying controls and a larger process-development burden.

For a low-price generic, direct compression or dry granulation generally offers a better cost profile than a complex wet-granulated product unless performance data justify the additional process steps.

What formulation patents protect Precose or acarbose products?

The original acarbose and Precose patent estate is mature. Core composition-of-matter and early formulation protections have expired or reached the end of their effective U.S. terms. A current product developer should not expect meaningful U.S. exclusivity from the original Precose brand patents.

IP category	Current commercial assessment
Acarbose active ingredient	Mature and off-patent
Original Precose composition	Historical protection; no current core exclusivity expected
Conventional immediate-release tablet	Generally open generic field
Specific excipient combination	Potentially protectable only if technically distinct and non-obvious
Orally disintegrating or taste-masked product	Possible formulation opportunity, subject to patentability and regulatory support
Method of use	Original diabetes-use protection is mature; new patient-selection claims would require clinical support
Manufacturing process	Process patents may exist by jurisdiction, but routine processes are unlikely to create broad market barriers

The risk is not the expired Precose estate. The risk is later-filed patents covering a particular salt, particle size, manufacturing process, taste-masking system, or novel dosage form. Freedom-to-operate analysis should therefore focus on current assignee portfolios and national filings rather than historical Precose patents alone.

What is the FDA regulatory status and Orange Book position for Precose?

Precose was approved in the United States for type 2 diabetes, and acarbose tablets are available through generic competition. FDA labeling identifies the immediate-release tablet strengths and meal-associated dosing instructions.[1]

The commercial reference-product position is less important than the generic product pathway because the active ingredient is established and the original brand exclusivity period has ended. For a conventional acarbose tablet, an ANDA is the expected route if the proposed product matches the reference product in active ingredient, dosage form, strength, route, and essential performance characteristics.

Regulatory question	Assessment
FDA-approved active ingredient	Yes
New chemical entity exclusivity	Expired
Current brand-based U.S. exclusivity	None expected
Conventional generic pathway	ANDA
Paragraph IV relevance	Limited for expired core patents; potentially relevant to later-listed patents
Orange Book strategy	Review current reference-product and patent listings before filing
Novel dosage-form pathway	May require additional clinical, bioequivalence, or efficacy support depending on differences

A conventional tablet may qualify for an abbreviated development program, but the sponsor must address the regulatory treatment of an orally acting, minimally absorbed product. Traditional plasma pharmacokinetics may not fully characterize local gastrointestinal performance. FDA’s product-specific expectations, if available, should control the study design.[2]

What generic entry risks exist for acarbose?

Generic entry risk is high because the product is mature, the dosage form is conventional, and the main active pharmaceutical ingredient is available from multiple potential suppliers.

The principal barriers are commercial rather than patent-based:

1. Low reimbursement and limited price headroom.
2. Small or declining brand demand in markets dominated by newer diabetes therapies.
3. Gastrointestinal tolerability that can limit persistence.
4. Need for reliable supply of a specialized carbohydrate-like active ingredient.
5. Regulatory complexity for any formulation that departs from the conventional tablet.

A generic manufacturer can compete through reliable supply, lower tablet cost, contract manufacturing, regional registration, or a differentiated presentation. A standalone premium price is difficult to justify without a meaningful adherence or tolerability benefit.

What commercial opportunities exist for acarbose excipient innovation?

Smaller tablets and improved swallowability

Acarbose is taken three times daily, so tablet size has an outsized adherence impact. A high-load direct-compression system, better compactibility, or a bilayer design could reduce tablet burden, although any bilayer or multiparticulate approach would require careful performance validation.

Orally disintegrating tablets

An orally disintegrating tablet could target patients who have difficulty swallowing or who need a portable meal-time product. The principal technical challenges are:

• Acarbose dose load.
• Taste and mouthfeel.
• Moisture sensitivity.
• Fast disintegration without friability.
• Avoidance of excessive sweeteners or polyols that may worsen gastrointestinal symptoms.

Taste masking is particularly important because acarbose must contact the mouth before reaching the intestine in an orally disintegrating format.

Chewable or dispersible tablets

A chewable product could support meal-associated administration, but it would require strong taste-masking controls. A dispersible tablet may offer a practical alternative for patients who cannot swallow tablets, but it would increase packaging and stability requirements.

Unit-dose and adherence packaging

Because dosing occurs with meals, calendar blister packs, meal-labeled unit doses, or portable sachets may create more commercial value than a new excipient alone. Packaging can protect against moisture and help patients coordinate the product with breakfast, lunch, and dinner.

Combination products

Acarbose could be paired commercially with other antihyperglycemic therapies, but combination products face clinical, regulatory, and market-positioning barriers. New combinations would need evidence that the combination improves glycemic control or adherence without worsening gastrointestinal tolerability.

Regional low-cost supply

The clearest opportunity is a cost-efficient generic platform for markets where acarbose remains clinically used. China and parts of Asia have historically had greater acarbose utilization than the United States, creating opportunities for local registration, contract manufacturing, and differentiated packaging. Geographic value depends on local reimbursement, treatment guidelines, and existing generic density.

How does acarbose compare with newer diabetes drugs?

Acarbose competes against metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and insulin. Newer agents generally have stronger commercial momentum because of cardiovascular, renal, weight, or convenience benefits.

Product class	Main advantage over acarbose	Acarbose advantage
Metformin	Lower cost and stronger guideline position	Useful postprandial mechanism; no systemic hypoglycemia as monotherapy
Sulfonylureas	Potent and inexpensive	Lower intrinsic hypoglycemia concern when used alone
DPP-4 inhibitors	Once-daily dosing and improved convenience	Lower manufacturing cost
SGLT2 inhibitors	Cardiovascular and renal outcomes for selected agents	No urinary glucose mechanism or genital-infection concern
GLP-1 receptor agonists	Weight loss and potent glucose lowering	Oral solid dosage form and low acquisition cost
Insulin	Strong glucose-lowering effect	No injection requirement

Acarbose is most commercially defensible where price, oral administration, postprandial control, and local prescribing practice matter more than weight loss or cardiorenal outcomes.

Which companies are challenging Precose exclusivity?

The relevant competitive field consists mainly of generic acarbose manufacturers rather than branded challengers. Generic competition is expected to include companies with established oral solid-dose infrastructure and regional diabetes portfolios.

For a conventional product, Paragraph IV litigation is less likely to be the primary market event because the original Precose patent position is mature. Litigation risk would increase if a sponsor sought approval for a product covered by a later-listed formulation or process patent. Any current Orange Book listing and court docket should be checked before launch planning.

How strong is the patent estate for an acarbose reformulation?

A reformulation patent could be commercially useful if it claims a measurable technical improvement, such as:

• Faster disintegration at reduced compression force.
• Improved content uniformity across low-dose tablets.
• Reduced tablet mass.
• Enhanced stability under high humidity.
• Taste masking without delayed gastrointestinal release.
• A defined particle-size distribution or granulation process.
• A validated dispersible or orally disintegrating presentation.

A patent limited to substituting one conventional filler for another would face a higher obviousness risk. Stronger protection would combine composition, process parameters, performance data, and a clinically relevant benefit.

What licensing and manufacturing opportunities exist?

Licensing opportunities are more likely to involve manufacturing know-how, regional distribution, or a differentiated dosage form than the original Precose brand.

Potential deal structures include:

• Supply agreements for acarbose API and finished tablets.
• Regional licensing for orally disintegrating or dispersible products.
• Contract manufacturing for low-cost markets.
• Co-development of adherence packaging.
• Technology transfer for direct-compression or dry-granulation processes.
• Portfolio deals combining acarbose with other mature oral antidiabetics.

Manufacturing diligence should cover API impurity controls, microbial limits, powder flow, blend segregation, compression behavior, moisture stability, and supply continuity. Acarbose’s carbohydrate-like structure may require more specialized API manufacturing than standard small-molecule generics.

Key Takeaways

• Precose is the former Bayer brand for acarbose, an established immediate-release oral antidiabetic.
• The original U.S. exclusivity position is mature; commercial value is primarily generic and formulation-based.
• The core excipient platform uses conventional tablet ingredients, including starch, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate.
• Rapid disintegration, dose uniformity, low tablet burden, and moisture control are the central formulation objectives.
• The best commercial opportunities are smaller tablets, orally disintegrating or dispersible products, adherence packaging, regional generic supply, and manufacturing-cost reduction.
• Acarbose has limited premium pricing power against newer diabetes therapies, so a differentiated product needs a clear adherence, tolerability, or supply advantage.
• Patent value is more likely to arise from a technically defined reformulation or manufacturing process than from the original Precose composition.
• Generic entry risk is high, while Paragraph IV and settlement issues are likely to be secondary unless later formulation or process patents are listed.

FAQs

Is acarbose still protected by patents?

The original acarbose and Precose patent protections are mature and are not expected to block conventional generic tablets in the United States. Later formulation or process patents must be reviewed separately.

Can acarbose be formulated as an extended-release tablet?

Extended release is not the natural target because acarbose acts locally during meal-associated carbohydrate digestion. A modified-release design could reduce synchronization with meals and would require substantial performance justification.

Which excipient is most important for acarbose tablet disintegration?

The disintegrant system is central, but performance depends on the full formulation, including filler-binder selection, compression force, lubricant level, granulation method, and tablet porosity.

Is an acarbose orally disintegrating tablet commercially attractive?

It may be attractive for patients with swallowing difficulty or meal-time adherence problems. The main development barriers are high dose load, taste masking, mouthfeel, moisture sensitivity, and proof that rapid oral disintegration does not compromise gastrointestinal performance.

Does acarbose have biosimilar competition?

No. Acarbose is a chemically synthesized small-molecule drug, so competition proceeds through generic drug pathways rather than biosimilar approval pathways.

References

1. Bayer Pharmaceuticals Corporation. (2009). Precose (acarbose) tablets prescribing information. U.S. Food and Drug Administration labeling archive.

2. U.S. Food and Drug Administration. (2018). ANDA submissions: Content and format of abbreviated new drug applications. FDA.

3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. FDA, Orange Book.

4. American Diabetes Association Professional Practice Committee. (2024). Standards of care in diabetes: Pharmacologic approaches to glycemic treatment. Diabetes Care, 47(Supplement 1).

5. DailyMed. (2024). Acarbose tablet labeling. U.S. National Library of Medicine.